Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 796.28 USD 3.71% Market Closed
Market Cap: 755.9B USD
Have any thoughts about
Eli Lilly and Co?
Write Note
Section:
 

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 272.74 USD. Compared to the current market price of 796.28 USD, Eli Lilly and Co is Overvalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
272.74 USD
Overvaluation 66%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

18.5
P/S
P/S
Price to Sales
18.5
vs History
19
vs Industry
8
Median 3Y
14.6
Median 5Y
10
Industry
2.5
Forward
16.4
More Details
90.4
P/E
P/E
Price to Earnings
90.4
vs History
23
vs Industry
2
Median 3Y
67.6
Median 5Y
47.7
Industry
21.8
Forward
60
More Details
125.4
P/OCF
P/OCF
Price to OCF
125.4
vs History
19
vs Industry
2
Median 3Y
65.6
Median 5Y
36.2
Industry
16.1
More Details
92.5
P/FCFE
P/FCFE
Price to FCFE
92.5
vs History
25
vs Industry
2
Median 3Y
81.5
Median 5Y
50.8
Industry
23.8
More Details
53.1
P/B
P/B
Price to Book Value
53.1
vs History
19
vs Industry
1
Median 3Y
37
Median 5Y
34.7
Industry
2.1
More Details
19.1
EV/S
EV/S
Enterprise Value to Sales
19.1
vs History
17
vs Industry
8
Median 3Y
15.1
Median 5Y
10.4
Industry
2.7
Forward
17
More Details
23.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
23.6
vs History
19
vs Industry
7
Median 3Y
19.4
Median 5Y
13.7
Industry
5.2
More Details
48.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
48.5
vs History
30
vs Industry
5
Median 3Y
46.3
Median 5Y
30.2
Industry
13.5
Forward
48
More Details
54.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
54.2
vs History
31
vs Industry
5
Median 3Y
54.1
Median 5Y
36.1
Industry
16.8
Forward
53.2
More Details
129.6
EV/OCF
EV/OCF
Enterprise Value to OCF
129.6
vs History
19
vs Industry
1
Median 3Y
68
Median 5Y
37.8
Industry
15.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
4
Median 3Y
49.2
Median 5Y
41.3
Industry
19.3
More Details
11.3
EV/IC
EV/IC
Enterprise Value to IC
11.3
vs History
19
vs Industry
8
Median 3Y
9
Median 5Y
6.8
Industry
1.9
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
US
Eli Lilly and Co
NYSE:LLY
Average P/S: 382 947.7
18.5
109%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 32.4
90.4
446%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 437.2
48.5
195%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 869.3
54.2
211%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.